With over 25 years of experience in the biotechnology sector, Jordi Ruano has built a solid track record in the design, scale-up, and operation of biotech facilities and processes under current EU Good Manufacturing Practices (GMP). His career has encompassed leadership in upstream and downstream processing, as well as extensive expertise in the manufacturing of complex biological products, including viral antigens, recombinant proteins from mammalian and microbial systems, antigens from SPF embryonated eggs and antigens from parasites. In addition, he has overseen formulation, aseptic filling, and lyophilization of vaccines and pharmaceutical products.
Jordi currently serves as Executive Director of Operations for the Human Health Division at HIPRA, where he leads operational strategy and execution to support the company’s growing portfolio in human health. In this capacity, he is responsible for ensuring operational excellence across manufacturing, quality, supply chain, and process improvement activities, while fostering innovation and scalability to meet global health needs.
HIPRA is a biopharmaceutical company focused on the prevention of infectious diseases in both animal and human health. Under the motto “Building immunity for a healthier world”, HIPRA offers a broad portfolio of innovative vaccines and prevention solutions, with subsidiaries in over 40 countries and a distribution network spanning all five continents.
